The agency says the generic drug maker needs to resolve issues at a manufacturing plant in California.
Metal pros expect moderate gains this year, but certainly no renewed rush for this precious metal.
Biogen Idec, Pfizer, Bristol-Myers and Celgene are among companies awaiting US approval of key treatments.
Missed Starbucks on its way up many years ago? Here are the names you should be watching now.
The short-term market is hard to read, but the long-term trend of this tech titan provides some insight.
The failure raises more questions about treatments designed to raise good cholesterol levels.
The biotech's partner says the vaccine didn't meet a study goal to show effectiveness. Stock drops almost 60%.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Investors don't have to settle for low returns -- if they're willing to do a little homework.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.